Back to search
FDAFDA · Food and drugs·Recall number D-0845-2022

Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), packaged in a 10 mL Multiple-Dose vial inside a carton, Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Manufactured for: Mylan Specialty L.P., Morgantown, WV 26505, NDC 49502-393-80

Published May 4, 2022 · Recall initiated: April 12, 2022

Summary

FDA records drug Class I recall D-0845-2022, published May 4, 2022 and initiated April 12, 2022. Recalling firm: Mylan Pharmaceuticals Inc; Status: Terminated; Reported quantity: 89,665 vials; Lot: Lot #: BF21002800, Exp 8/2023. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Missing label on the vial

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mylan Pharmaceuticals Inc
Distributor
USA nationwide.
Lot
Lot #: BF21002800, Exp 8/2023
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), packaged in a 10 mL Multiple-Dose vial inside a carton, Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Manufactured for: Mylan Specialty L.P., Morgantown, WV 26505, NDC 49502-393-80 recalled?

Yes. FDA published recall D-0845-2022 on May 4, 2022. Reported hazard: Labeling: Missing label on the vial

What should I do if I have this product?

Voluntary: Firm initiated · Press Release